Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Spriggs

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Investigational New Drugs|March 17, 2007
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumorsMartee L Hensley, Don Dizon, Felicia Derosa, et al.
Gynecologic Oncology|February 24, 2006
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioningMartee L Hensley, Denise D Correa, Howard Thaler, et al.
Gynecologic Oncology|January 13, 2009
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective studyMartee L Hensley, Nicole Ishill, Robert Soslow, et al.
Gynecologic Oncology|June 12, 2003
Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of lifeMartee L Hensley, Mark E Robson, Noah D Kauff, et al.
Cancer|October 6, 2007
A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remissionDouglas Levine, Kay Park, Margrit Juretzka, et al.
Frontiers in Immunology|May 3, 2021
Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF InhibitionOladapo O Yeku, Thapi Dharma Rao, Ian Laster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Using patients as their own controls for cost evaluation of phase I clinical trialsEric J Sherman, David M Rubin, Ennapadam Venkatraman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2004
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinomaPaul Sabbatini, Carol Aghajanian, Don Dizon, et al.
Cancer|January 22, 2009
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group studyKristin K Zorn, Chunqiao Tian, William P McGuire, et al.
Cancer Research|October 19, 2005
Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignanciesGregory M Springett, Lynn Bonham, Amanda Hummer, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Investigational New Drugs|March 17, 2007
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumorsMartee L Hensley, Don Dizon, Felicia Derosa, et al.
Gynecologic Oncology|February 24, 2006
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioningMartee L Hensley, Denise D Correa, Howard Thaler, et al.
Gynecologic Oncology|January 13, 2009
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective studyMartee L Hensley, Nicole Ishill, Robert Soslow, et al.
Gynecologic Oncology|June 12, 2003
Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of lifeMartee L Hensley, Mark E Robson, Noah D Kauff, et al.
Cancer|October 6, 2007
A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remissionDouglas Levine, Kay Park, Margrit Juretzka, et al.
Frontiers in Immunology|May 3, 2021
Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF InhibitionOladapo O Yeku, Thapi Dharma Rao, Ian Laster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Using patients as their own controls for cost evaluation of phase I clinical trialsEric J Sherman, David M Rubin, Ennapadam Venkatraman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2004
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinomaPaul Sabbatini, Carol Aghajanian, Don Dizon, et al.
Cancer|January 22, 2009
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group studyKristin K Zorn, Chunqiao Tian, William P McGuire, et al.
Cancer Research|October 19, 2005
Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignanciesGregory M Springett, Lynn Bonham, Amanda Hummer, et al.
Pageof 5